The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

Katherine A. Michaelis, Mason A. Norgard, Xinxia Zhu, Peter R. Levasseur, Shamilene Sivagnanam, Shannon M. Liudahl, Kevin G. Burfeind, Brennan Olson, Katherine R. Pelz, Diana M. Angeles Ramos, H. Carlo Maurer, Kenneth P. Olive, Lisa M. Coussens, Terry K. Morgan and Daniel L. Marks ()
Additional contact information
Katherine A. Michaelis: Oregon Health & Science University
Mason A. Norgard: Oregon Health & Science University
Xinxia Zhu: Oregon Health & Science University
Peter R. Levasseur: Oregon Health & Science University
Shamilene Sivagnanam: Oregon Health & Science University
Shannon M. Liudahl: Oregon Health & Science University
Kevin G. Burfeind: Oregon Health & Science University
Brennan Olson: Oregon Health & Science University
Katherine R. Pelz: Oregon Health & Science University
Diana M. Angeles Ramos: Oregon Health & Science University
H. Carlo Maurer: Columbia University Medical Center
Kenneth P. Olive: Columbia University Medical Center
Lisa M. Coussens: Oregon Health & Science University
Terry K. Morgan: Oregon Health & Science University
Daniel L. Marks: Oregon Health & Science University

Nature Communications, 2019, vol. 10, issue 1, 1-15

Abstract: Abstract A priority in cancer research is to innovate therapies that are not only effective against tumor progression but also address comorbidities such as cachexia that limit quality and quantity of life. We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC). In vivo, tumors from two of three cell lines were R848-sensitive, resulting in smaller tumor mass, increased immune complexity, increased CD8+ T-cell infiltration and activity, and decreased Treg frequency. R848-treated mice demonstrated improvements in behavioral and molecular cachexia manifestations, resulting in a near-doubling of survival duration. Knockout mouse studies revealed that stromal, not neoplastic, TLR7 is requisite for R848-mediated responses. In patient samples, we found Tlr7 is ubiquitously expressed in stroma across all stages of pancreatic neoplasia, but epithelial Tlr7 expression is relatively uncommon. These studies indicate immune-enhancing approaches including R848 may be useful in PDAC and cancer-associated cachexia.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-019-12657-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12657-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-12657-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().